CARE RATINGS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,090 INR | +1.14% |
|
+7.39% | +14.34% |
| May. 10 | Transcript : CARE Ratings Limited, Q4 2024 Earnings Call, May 10, 2024 | |
| May. 09 | CARE Ratings Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 55% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 29.69 and 25.72 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Professional Information Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +14.34% | 385M | - | ||
| +3.27% | 73.65B | B+ | ||
| -2.21% | 645M | C | ||
| +17.15% | 289M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CARERATING Stock
- Ratings CARE Ratings Limited
